Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 364

1.

Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).

Maestre A, Muskus C, Duque V, Agudelo O, Liu P, Takagi A, Ntumngia FB, Adams JH, Sim KL, Hoffman SL, Corradin G, Velez ID, Wang R.

PLoS One. 2010 Jul 15;5(7):e11437. doi: 10.1371/journal.pone.0011437.

2.

Duffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-duffy binding protein II (DBPII) immunity.

Souza-Silva FA, Torres LM, Santos-Alves JR, Tang ML, Sanchez BA, Sousa TN, Fontes CJ, Nogueira PA, Rocha RS, Brito CF, Adams JH, Kano FS, Carvalho LH.

PLoS One. 2014 Apr 7;9(4):e93782. doi: 10.1371/journal.pone.0093782. eCollection 2014.

3.

Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.

Zakeri S, Babaeekhou L, Mehrizi AA, Abbasi M, Djadid ND.

Am J Trop Med Hyg. 2011 Jun;84(6):944-50. doi: 10.4269/ajtmh.2011.11-0001.

4.

Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein.

Grimberg BT, Udomsangpetch R, Xainli J, McHenry A, Panichakul T, Sattabongkot J, Cui L, Bockarie M, Chitnis C, Adams J, Zimmerman PA, King CL.

PLoS Med. 2007 Dec;4(12):e337.

5.

The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants.

Kano FS, Souza-Silva FA, Torres LM, Lima BA, Sousa TN, Alves JR, Rocha RS, Fontes CJ, Sanchez BA, Adams JH, Brito CF, Pires DE, Ascher DB, Sell AM, Carvalho LH.

PLoS Negl Trop Dis. 2016 Dec 13;10(12):e0005177. doi: 10.1371/journal.pntd.0005177. eCollection 2016 Dec.

6.

Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria.

King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, Greenberg LJ, Siddiqui A, Howes RE, da Silva-Nunes M, Ferreira MU, Zimmerman PA.

Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20113-8. doi: 10.1073/pnas.1109621108. Epub 2011 Nov 28.

7.

Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast.

Herrera S, Gómez A, Vera O, Vergara J, Valderrama-Aguirre A, Maestre A, Méndez F, Wang R, Chitnis CE, Yazdani SS, Arévalo-Herrera M.

Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):44-9.

PMID:
16291766
8.

Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children.

Cole-Tobian JL, Michon P, Biasor M, Richards JS, Beeson JG, Mueller I, King CL.

Infect Immun. 2009 Sep;77(9):4009-17. doi: 10.1128/IAI.00158-09. Epub 2009 Jun 29.

9.

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection.

King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8363-8. doi: 10.1073/pnas.0800371105. Epub 2008 Jun 3.

10.

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.

Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, Chitnis CE, Chauhan VS.

Vaccine. 2007 Jul 9;25(28):5166-74. Epub 2007 May 21.

PMID:
17544179
11.

Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.

Ntumngia FB, Schloegel J, McHenry AM, Barnes SJ, George MT, Kennedy S, Adams JH.

Vaccine. 2013 Sep 13;31(40):4382-8. doi: 10.1016/j.vaccine.2013.07.002. Epub 2013 Jul 31.

12.

Immune responses to Plasmodium vivax pre-erythrocytic stage antigens in naturally exposed Duffy-negative humans: a potential model for identification of liver-stage antigens.

Wang R, Arevalo-Herrera M, Gardner MJ, Bonelo A, Carlton JM, Gomez A, Vera O, Soto L, Vergara J, Bidwell SL, Domingo A, Fraser CM, Herrera S.

Eur J Immunol. 2005 Jun;35(6):1859-68. Erratum in: Eur J Immunol. 2005 Jun;35(6):2006.

13.

Plasmodium vivax pre-erythrocytic-stage antigen discovery: exploiting naturally acquired humoral responses.

Molina DM, Finney OC, Arevalo-Herrera M, Herrera S, Felgner PL, Gardner MJ, Liang X, Wang R.

Am J Trop Med Hyg. 2012 Sep;87(3):460-9. doi: 10.4269/ajtmh.2012.12-0222. Epub 2012 Jul 23.

14.
15.

Comparative recognition by human IgG antibodies of recombinant proteins representing three asexual erythrocytic stage vaccine candidates of Plasmodium vivax.

Barbedo MB, Ricci R, Jimenez MC, Cunha MG, Yazdani SS, Chitnis CE, Rodrigues MM, Soares IS.

Mem Inst Oswaldo Cruz. 2007 Jun;102(3):335-9.

16.

Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians.

Nicolete VC, Frischmann S, Barbosa S, King CL, Ferreira MU.

J Infect Dis. 2016 Nov 15;214(10):1539-1546. Epub 2016 Aug 30.

17.
18.

Plasmodium simium, a Plasmodium vivax-related malaria parasite: genetic variability of Duffy binding protein II and the Duffy antigen/receptor for chemokines.

Camargos Costa D, Pereira de Assis GM, de Souza Silva FA, Araújo FC, de Souza Junior JC, Braga Hirano ZM, Satiko Kano F, Nóbrega de Sousa T, Carvalho LH, Ferreira Alves de Brito C.

PLoS One. 2015 Jun 24;10(6):e0131339. doi: 10.1371/journal.pone.0131339. eCollection 2015.

19.

A Novel Erythrocyte Binding Protein of Plasmodium vivax Suggests an Alternate Invasion Pathway into Duffy-Positive Reticulocytes.

Ntumngia FB, Thomson-Luque R, Torres Lde M, Gunalan K, Carvalho LH, Adams JH.

MBio. 2016 Aug 23;7(4). pii: e01261-16. doi: 10.1128/mBio.01261-16.

20.

Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC.

Batchelor JD, Malpede BM, Omattage NS, DeKoster GT, Henzler-Wildman KA, Tolia NH.

PLoS Pathog. 2014 Jan;10(1):e1003869. doi: 10.1371/journal.ppat.1003869. Epub 2014 Jan 9.

Supplemental Content

Support Center